Synaptogenix Inc (SNPX)

[runncoach]

What Dr Alkon was talking about Tuesday was the PKCe levels that were triggered and measured with the single dose in the 2a. That was part of the "efficacy" endpoint to the company and the drug dose given was effective in achieving that level. Obviously when they asked the patients specific questions hours later there wasn't a statistically significant improvement thus the language about cognition in the PR. Doesn't mean there was ZERO efficacy the way the company viewed all the variables. If it was simply the scores on a scale hours later then you are right and I get your point. That's not all the company was testing for however and they already knew it took multiple doses to get improved cognitive efficacy in animals. JMHO